RXi Pharmaceuticals Presents Additional Positive Phase 2 Efficacy Results for Combination of NeuVaxTM and Trastuzumab Breast Cancer at ASCO

RXi Pharmaceuticals Corporation RXII presented Phase 2 efficacy results for NeuVax™ in combination with trastuzumab (Herceptin®; Genentech/Roche) at the American Society of Clinical Oncology annual meeting. The poster entitled, “Sequential administration of trastuzumab and a CD8 T cell-eliciting HER-2/neu peptide vaccine in breast cancer patients compared to trastuzumab alone,” was presented during the “Breast Cancer HER2/ER” poster session on Monday, June 6, 2011. RXi is developing NeuVax, a CD8 T-cell eliciting immunotherapy, for the adjuvant treatment of low to intermediate HER2 expressing breast cancer.